{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T17:40:12Z","timestamp":1792777212484,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ejmech.2026.119427","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:09:50Z","timestamp":1792537790000},"page":"119427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Design, synthesis and evaluation of quinazoline-6-carbonitrile derivatives as novel covalent KRASG12C inhibitors for the treatment of NSCLC"],"prefix":"10.1016","volume":"321","author":[{"given":"Minxiong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuojie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongkai","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongdui","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiliang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9446-5117","authenticated-orcid":false,"given":"Fang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5324","key":"10.1016\/j.ejmech.2026.119427_bib1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1126\/science.277.5324.333","article-title":"The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic ras mutants","volume":"277","author":"Scheffzek","year":"1997","journal-title":"Science"},{"issue":"6330","key":"10.1016\/j.ejmech.2026.119427_bib2","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.aam7622","article-title":"Drugging RAS: know the enemy","volume":"355","author":"Papke","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119427_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119427_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1242\/jcs.238865","article-title":"Pumping the brakes on RAS - negative regulators and death effectors of RAS","volume":"133","author":"Harrell Stewart","year":"2020","journal-title":"J. Cell Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119427_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/1043-2760(94)90014-0","article-title":"The Sos (son of sevenless) protein","volume":"5","author":"Bar-Sagi","year":"1994","journal-title":"Trends Endocrinol. Metabol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119427_bib6","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2007.05.018","article-title":"GEFs and GAPs: critical elements in the control of small G proteins","volume":"129","author":"Bos","year":"2007","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.ejmech.2026.119427_bib7","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","article-title":"Biochemical and structural analysis of common cancer-associated KRAS mutations","volume":"13","author":"Hunter","year":"2015","journal-title":"Mol. Cancer Res."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119427_bib8","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119427_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMc2030638","article-title":"Distribution of KRASG12C somatic mutations across race, sex, and cancer type","volume":"384","author":"Nassar","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119427_bib10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"7477","key":"10.1016\/j.ejmech.2026.119427_bib11","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119427_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117391","article-title":"Design, synthesis and biological evaluation of pyrrolopyrimidine urea derivatives as novel KRASG12C inhibitors for the treatment of cancer","volume":"289","author":"Shang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119427_bib13","doi-asserted-by":"crossref","first-page":"6940","DOI":"10.1021\/acs.jmedchem.2c00369","article-title":"Discovery of AZD4625, a covalent allosteric inhibitor of the mutant GTPase KRASG12C","volume":"65","author":"Kettle","year":"2022","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119427_bib14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","article-title":"Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors","volume":"63","author":"Lanman","year":"2020","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119427_bib15","first-page":"470","article-title":"Sotorasib effective in KRAS-mutant NSCLC","volume":"18","author":"Sidaway","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119427_bib16","doi-asserted-by":"crossref","first-page":"105074","DOI":"10.1016\/j.ebiom.2024.105074","article-title":"Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis","volume":"102","author":"Ernst","year":"2024","journal-title":"EBioMedicine"},{"issue":"13","key":"10.1016\/j.ejmech.2026.119427_bib17","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","article-title":"Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer","volume":"63","author":"Fell","year":"2020","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119427_bib18","first-page":"1","article-title":"Adagrasib's efficacy sustained in KRASG12C NSCLC","volume":"13","year":"2023","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119427_bib19","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","article-title":"Efficacy and safety of adagrasib plus cetuximab in patients with KRASG12C-Mutated metastatic colorectal cancer","volume":"14","author":"Yaeger","year":"2024","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119427_bib20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-2600(24)00110-3","article-title":"Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial","volume":"12","author":"Li","year":"2024","journal-title":"Lancet Respir. Med."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119427_bib21","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s40265-024-02120-6","article-title":"Fulzerasib: first approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"issue":"15","key":"10.1016\/j.ejmech.2026.119427_bib22","doi-asserted-by":"crossref","first-page":"15386","DOI":"10.1021\/acs.jmedchem.4c03183","article-title":"Discovery of Fulzerasib (GFH925) for the treatment of KRAS G12C-Mutated solid tumors","volume":"68","author":"Jiang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119427_bib23","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s41591-024-03401-z","article-title":"Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial","volume":"31","author":"Shi","year":"2025","journal-title":"Nat. Med."},{"issue":"16_suppl","key":"10.1016\/j.ejmech.2026.119427_bib24","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1200\/JCO.2025.43.16_suppl.8520","article-title":"Sosimerasib monotherapy in patients with previously treated KRAS G12C\u2013mutated non-small cell lung cancer: primary results of a phase 2 study","volume":"43","author":"Zhong","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119427_bib25","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1021\/acs.jmedchem.4c02313","article-title":"Discovery of Elironrasib (RMC-6291), a potent and orally bioavailable, RAS(ON) G12C-Selective, covalent tricomplex inhibitor for the treatment of patients with RAS G12C-Addicted cancers","volume":"68","author":"Cregg","year":"2025","journal-title":"J. Med. Chem."},{"issue":"16_suppl","key":"10.1016\/j.ejmech.2026.119427_bib26","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2022.40.16_suppl.3141","article-title":"The distribution of genetic mutations correlated with resistance to KRASG12C inhibitors in Chinese patients with lung cancer","volume":"40","author":"Lin","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"S1","key":"10.1016\/j.ejmech.2026.119427_bib27","doi-asserted-by":"crossref","first-page":"35783","DOI":"10.1002\/cncr.35783","article-title":"Advances in the treatment of KRASG12C mutant non\u2013small cell lung cancer","volume":"131","author":"Shaverdashvili","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2026.119427_bib28","doi-asserted-by":"crossref","first-page":"109114","DOI":"10.1016\/j.bioorg.2025.109114","article-title":"Design, synthesis and evaluation of 1,2-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile derivatives as novel covalent inhibitors for the treatment of KRAS(G12C)-mutant NSCLC","volume":"166","author":"Yang","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119427_bib29","doi-asserted-by":"crossref","first-page":"114088","DOI":"10.1016\/j.ejmech.2021.114088","article-title":"Efficient targeted oncogenic KRAS(G12C) degradation via first reversible-covalent PROTAC","volume":"230","author":"Yang","year":"2022","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600872X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600872X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T17:20:22Z","timestamp":1792776022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342600872X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":29,"alternative-id":["S022352342600872X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119427","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and evaluation of quinazoline-6-carbonitrile derivatives as novel covalent KRASG12C inhibitors for the treatment of NSCLC","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119427","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119427"}}